Oncotarget

Research Papers:

Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis

Eun Ho Kim, Hyo Sook Song, Seung Hoon Yoo and Myonggeun Yoon _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:65125-65136. https://doi.org/10.18632/oncotarget.11372

Metrics: PDF 1200 views  |   HTML 1007 views  |   ?  


Abstract

Eun Ho Kim1, Hyo Sook Song2, Seung Hoon Yoo1, Myonggeun Yoon2

1Korea Institute of Radiological and Medical Sciences, Seoul, Korea

2Department of Bio-Convergence Engineering, Korea University, Seoul, Korea

Correspondence to:

Myonggeun Yoon, email: radioyoon@korea.ac.kr

Keywords: tumor treating fields, glioblastoma multiforme, NF-kB, metastasis, angiogenesis

Received: March 15, 2016     Accepted: August 10, 2016     Published: August 18, 2016

ABSTRACT

Treatment with alternating electric fields at an intermediate frequency (100–300 kHz), referred to as tumor treating fields (TTF) therapy, inhibits cancer cell proliferation. In the present study, we demonstrated that TTF application suppressed the metastatic potential of U87 and U373 glioblastoma cell lines via the NF-kB, MAPK and PI3K/AKT signaling pathways. Wound-healing and transwell assays showed that TTF suppressed cell migration and invasion compared with controls. Soft agar and three-dimensional culture assays showed that TTF inhibited both anchorage-dependent (cell proliferation) and anchorage-independent (colony formation) GBM cell growth. TTF dysregulated epithelial-to-mesenchymal transition-related genes, such as vimentin and E-cadherin, which partially accounted for TTF inhibition of cell migration and invasion. We further demonstrated that TTF application suppressed angiogenesis by downregulating VEGF, HIF1α and matrix metalloproteinases 2 and 9. TTF also inhibited NF-kB transcriptional activity. Collectively, our findings show that TTF represents a promising novel anti-invasion and anti-angiogenesis therapeutic strategy for use in GBM patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11372